Product Description
For the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia; The investigators hypothesize that CX-01 will disrupt the bone marrow microenvironment and increase the cytotoxic effects of azacitidine on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) hematopoietic stem cells by disrupting the High-mobility group box protein 1 (HMGB1) interaction with toll-like receptor 4 (TLR4) and receptors for advanced glycation end products (RAGE), the CXC chemokine CXCL12/chemokine receptor 4 (CXCR4) axis, and by disrupting other leukocyte and vascular adhesion molecules. In addition, CX-01 may also help promote count recovery after treatment given its affinity for platelet factor-4 (PF4). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02995655)
Mechanisms of Action: CXCL12 Inhibitor,CXCR4 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chimerix
Company Location: DURHAM NC 27713
Company CEO: Michael A. Sherman
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Acute Myeloid Leukemia
Phase 1: Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CNTX-CX-01-2015-AML-1 | P2 |
Completed |
Acute Myeloid Leukemia |
2019-06-01 |
|
| CNTX-CX-01-2016-MDS-1 | P1 |
Completed |
Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome |
2018-09-13 |